Pinsent Masons Advises Accord Healthcare in Exclusive Licence Agreement with Myovant Sciences to Commercialise ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
14 Jun 2022 | 03:35 pm |
Pinsent Masons represented Accord Healthcare Ltd in an exclusive license agreement with Myovant Sciences to commercialise relugolix, Myovant’s advanced hormone-sensitive prostate cancer treatment, under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey.
Under the terms of the agreement, Myovant will receive an upfront payment of US$50 million, and is eligible to receive milestones which could total up to a further US$90.5 million. Myovant will continue to lead the global development of relugolix and provide initial product supply to Accord. Accord will be responsible for certain local clinical development, all commercialization for its territories, and has the option to manufacture relugolix in the future.
The Pinsent Masons transactions team was led by Life Sciences Transactions partner Gina Bicknell, with primary support from solicitor Kiah York and legal director Mario Subramaniam.
Latest press releases
Show me all press releasesPinsent Masons advises Levy Merchandising on its first National Team Partnership
Multinational law firm Pinsent Masons has advised sports merchandising and athleisure-wear company Levy Merchandising on a landmark technical partnership and retail outsourcing agreement with the Football Association of Wales.
Pinsent Masons advises Horizon 3 Healthcare on investment in Xeltis
Multinational law firm Pinsent Masons has advised Horizon 3 Healthcare as lead investor in an additional €20.5 million funding round for Xeltis, a clinical-stage medtech company developing transformative implantable medical devices.
Pinsent Masons appoints inaugural financial regulatory consulting head
Multinational law firm Pinsent Masons has hired Ian Stott to found and lead its financial regulatory consulting practice. Ian will join Vario, the legal services delivery arm of Pinsent Masons, and work with specialists across the firm to enhance existing offerings and spearhead the development of its non-legal regulatory conduct and financial crime advisory and remediation services.
People who viewed this press release also viewed
Show me all press releasesPinsent Masons advises Horizon 3 Healthcare on investment in Xeltis
Multinational law firm Pinsent Masons has advised Horizon 3 Healthcare as lead investor in an additional €20.5 million funding round for Xeltis, a clinical-stage medtech company developing transformative implantable medical devices.
Pinsent Masons elects John Maciver as Senior Partner
Multinational law firm Pinsent Masons has elected John Maciver as Senior Partner.
Pinsent Masons strengthens its competition law practice with the appointment of Christian Peeters
Multinational law firm Pinsent Masons is strengthening its Antitrust, Competition & Trade practice at its Dusseldorf/Germany office with the appointment of Christian Peeters, LL.M., effective 1 July 2026.
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on
Location contacts
Europe: [email protected]
Asia: [email protected]
Middle East: [email protected]
Australia: [email protected]